Literature DB >> 15308712

R5 human immunodeficiency virus type 1 (HIV-1) replicates more efficiently in primary CD4+ T-cell cultures than X4 HIV-1.

Becky Schweighardt1, Ann-Marie Roy, Duncan A Meiklejohn, Edward J Grace, Walter J Moretto, Jonas J Heymann, Douglas F Nixon.   

Abstract

In this report, we present evidence that R5 human immunodeficiency virus type 1 (HIV-1) replicates more efficiently in primary CD4+ T cells than X4 HIV-1. By comparing CD3/CD28-costimulated CD4+ T-cell cultures infected by several X4 and R5 HIV-1 strains, we determined that R5-infected CD4+ T cells produce more virus over time than X4-infected CD4+ T cells. In the first comparison, we found that more cells were infected by the X4-tropic strain LAI than by the R5-tropic strain JR-CSF and yet that higher levels of viral production were detected in the R5-infected cultures. The differential viral production was partially due to the severe cytopathic effects of the X4 virus. We also compared cultures infected with the isogenic HIV-1 strains NL4-3 (X4) and 49.5 (R5). We found that fewer cells were infected by the R5 strain, and yet similar levels of viral production were detected in both infected cultures. Cell death played less of a role in the differential viral production of these strains, as the cell viability remained comparable in both X4- and R5-infected cultures over time. The final comparison involved the primary R5-tropic isolate KP1 and the primary dual-tropic isolate KP2. Although both strains infected similar numbers of cells and induced comparable levels of cytopathicity, viral production was considerably higher in the R5-infected culture. In summary, these data demonstrate that R5 HIV-1 has an increased capacity to replicate in costimulated CD4+ T cells compared to X4 HIV-1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308712      PMCID: PMC506961          DOI: 10.1128/JVI.78.17.9164-9173.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells.

Authors:  Gang Meng; Xiping Wei; Xiaoyun Wu; Marty T Sellers; Julie M Decker; Zina Moldoveanu; Jan M Orenstein; Martin F Graham; John C Kappes; Jiri Mestecky; George M Shaw; Phillip D Smith
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

2.  Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease.

Authors:  B Schramm; M L Penn; R F Speck; S Y Chan; E De Clercq; D Schols; R I Connor; M A Goldsmith
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue.

Authors:  M L Penn; J C Grivel; B Schramm; M A Goldsmith; L Margolis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

4.  Differential effects of CD28 costimulation on HIV production by CD4+ cells.

Authors:  E Barker; K N Bossart; J A Levy
Journal:  J Immunol       Date:  1998-12-01       Impact factor: 5.422

5.  Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status.

Authors:  J F Kreisberg; D Kwa; B Schramm; V Trautner; R Connor; H Schuitemaker; J I Mullins; A B van't Wout; M A Goldsmith
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  Cytopathic effects of non-syncytium-inducing and syncytium-inducing human immunodeficiency virus type 1 variants on different CD4(+)-T-cell subsets are determined only by coreceptor expression.

Authors:  D Kwa; J Vingerhoed; B Boeser-Nunnink; S Broersen; H Schuitemaker
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells.

Authors:  Andreas Jekle; Oliver T Keppler; Erik De Clercq; Dominique Schols; Mark Weinstein; Mark A Goldsmith
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 8.  HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion.

Authors:  Haynes W Sheppard; Connie Celum; Nelson L Michael; Stephen O'Brien; Michael Dean; Mary Carrington; Dale Dondero; Susan P Buchbinder
Journal:  J Acquir Immune Defic Syndr       Date:  2002-03-01       Impact factor: 3.731

9.  Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence.

Authors:  Andreas Jekle; Birgit Schramm; Prerana Jayakumar; Verena Trautner; Dominique Schols; Erik De Clercq; John Mills; Suzanne M Crowe; Mark A Goldsmith
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells.

Authors:  D A Eckstein; M P Sherman; M L Penn; P S Chin; C M De Noronha; W C Greene; M A Goldsmith
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

View more
  15 in total

1.  Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection.

Authors:  Gilad Doitsh; Nicole L K Galloway; Xin Geng; Zhiyuan Yang; Kathryn M Monroe; Orlando Zepeda; Peter W Hunt; Hiroyu Hatano; Stefanie Sowinski; Isa Muñoz-Arias; Warner C Greene
Journal:  Nature       Date:  2014-01-23       Impact factor: 49.962

2.  Human immunodeficiency virus persistence and production in T-cell development.

Authors:  Kevin B Gurney; Christel H Uittenbogaart
Journal:  Clin Vaccine Immunol       Date:  2006-09-20

Review 3.  Dissecting How CD4 T Cells Are Lost During HIV Infection.

Authors:  Gilad Doitsh; Warner C Greene
Journal:  Cell Host Microbe       Date:  2016-03-09       Impact factor: 21.023

4.  Methamphetamine inhibits HIV-1 replication in CD4+ T cells by modulating anti-HIV-1 miRNA expression.

Authors:  Chinmay K Mantri; Jyoti V Mantri; Jui Pandhare; Chandravanu Dash
Journal:  Am J Pathol       Date:  2013-10-26       Impact factor: 4.307

5.  Distinct mechanisms regulate IL1B gene transcription in lymphoid CD4 T cells and monocytes.

Authors:  Sree H Pulugulla; Thomas A Packard; Nicole L K Galloway; Zachary W Grimmett; Gilad Doitsh; Juraj Adamik; Deborah L Galson; Warner C Greene; Philip E Auron
Journal:  Cytokine       Date:  2018-10-06       Impact factor: 3.861

6.  Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes.

Authors:  Wei Zou; Paul W Denton; Richard L Watkins; John F Krisko; Tomonori Nochi; John L Foster; J Victor Garcia
Journal:  Retrovirology       Date:  2012-05-28       Impact factor: 4.602

7.  Fluorescent Reporter Signals, EGFP, and DsRed, Encoded in HIV-1 Facilitate the Detection of Productively Infected Cells and Cell-Associated Viral Replication Levels.

Authors:  Kazutaka Terahara; Takuya Yamamoto; Yu-Ya Mitsuki; Kentaro Shibusawa; Masayuki Ishige; Fuminori Mizukoshi; Kazuo Kobayashi; Yasuko Tsunetsugu-Yokota
Journal:  Front Microbiol       Date:  2012-01-10       Impact factor: 5.640

8.  Differential role of autophagy in CD4 T cells and macrophages during X4 and R5 HIV-1 infection.

Authors:  Lucile Espert; Mihayl Varbanov; Véronique Robert-Hebmann; Sophie Sagnier; Ian Robbins; Françoise Sanchez; Virginie Lafont; Martine Biard-Piechaczyk
Journal:  PLoS One       Date:  2009-06-03       Impact factor: 3.240

9.  A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro.

Authors:  Chien-Hsing Chang; Jorma Hinkula; Meiyu Loo; Tina Falkeborn; Rongxiu Li; Thomas M Cardillo; Edmund A Rossi; David M Goldenberg; Britta Wahren
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

10.  Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1.

Authors:  Erhard Kopetzki; Andreas Jekle; Changhua Ji; Eileen Rao; Jun Zhang; Stephan Fischer; Nick Cammack; Surya Sankuratri; Gabrielle Heilek
Journal:  Virol J       Date:  2008-05-01       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.